Pro
|
Ethical
|
Patient autonomy
|
X10,41
|
X10,41
|
X39
|
X5
|
Evidence of non-maleficence
|
X10,40,41
|
X10,40,41
| | |
Social and legal
|
Cost and suffering reduction
|
X38
|
X38
| | |
Favors Alzheimer’s disease prevention
|
X10
|
X10
| | |
Psychological and behavioral
|
Enables early decision making
|
X10,38,41
|
X10,38,41
|
X39
|
X5
|
Clarifying effect of correct diagnosis
|
X38
|
X38
|
X39
|
X5
|
Relief related to negative amyloid PET
|
X38,41
|
X38,41
| | |
Satisfies need for risk information
|
X41
|
X41
| | |
PET imaging characteristics
|
Amyloid PET imaging is validated
| | |
X39
| |
Clinical significance of amyloid PET
| | | |
X5
|
Contra
|
Ethical
|
Non-maleficence
|
X10,38,41
|
X10,38,41
|
X39
|
X5
|
Lack of effective intervention
|
X10,38
|
X10,38
|
X39
| |
Therapeutic misconception
|
X2
|
X2
| | |
Social and legal
|
Unwanted personal implications
|
X38,41
|
X10,38,41
| |
X5
|
Social stigmatization
|
X38,41
|
X38,41
| | |
Psychological and behavioral
|
Risk of psychological distress
|
X10,38,41
|
X10,38,41
| |
X5
|
Risk of false reassurance after negative PET
|
X10,41
|
X10,41
|
X39
| |
Misinterpretation of positive amyloid PET
|
X41
|
X41
| | |
PET imaging characteristics
|
Challenges related to inconclusive scans
|
X10,38
|
X10,38
| |
X5
|
Limited predictive value at level of individual
|
X10,41
|
X10,41
| | |
Variation on interpretation of PET results
|
X10
|
X10
| | |